Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography.
Tetrahydropapaveroline (THP) concentrations were measured in the urine of Parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy, using a method that employs a separation scheme that selectively isolates THP from urine and utilizes the Pictet-Spengler condensation of THP with formaldehyde combined with high-performance liquid chromatography for identification and determination. The mean (+/- S.D.) recoveries of THP from normal urine with 0.2 pmol/ml added and from Parkinsonian patients' urines with 0.5 pmol/ml added were 48.6 +/- 5.7 and 44.6 +/- 3.1%, respectively. Three Parkinsonian patients who were receiving either 250, 750 or 1000 mg of L-dopa (as Sinemet) daily had 24-h urinary THP excretion levels of 989, 1017 and 1600 pmol, respectively.
Cashaw
J L
JL
Veterans Affairs Medical Center, Houston, TX 77030.
D000327:Adsorption; D000537:Aluminum Oxide; D000978:Antiparkinson Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002230:Carbidopa / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002411:Cation Exchange Resins; D002851:Chromatography, High Pressure Liquid; D002852:Chromatography, Ion Exchange; D004338:Drug Combinations; D004563:Electrochemistry; D006801:Humans; D007980:Levodopa / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy / Q000652:urine*; D012117:Resins, Synthetic; D012821:Silanes; D013765:Tetrahydropapaveroline / Q000652:urine*
D000978:Antiparkinson Agents; D002411:Cation Exchange Resins; D004338:Drug Combinations; D012117:Resins, Synthetic; D012821:Silanes; C009265:carbidopa, levodopa drug combination; C024779:octadecylsilane; D007980:Levodopa; D013765:Tetrahydropapaveroline; C026257:Bio-Rex 70; D000537:Aluminum Oxide; D002230:Carbidopa